TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11100963
Drug: Protein-repair therapy
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-repair therapy including naturally occurring compounds (isoflavonoids), aminoglycoside antibiotics, butyrate analogues, phosphodiesterase inhibitors, adenosine nucleotides, designer compounds (benzo[c]quinoliziniums), small peptide replacements
Study: 6414955
Drug: Deroctyl (sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deroctyl (sustained-release capsules)
Study: 6414955
Drug: Euglucon (regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglucon (regular tablets)
Study: 26961114
Drug: Intensive statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive statin therapy (target LDL-C <70 mg/dL)
Study: 26961114
Drug: Standard statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard statin therapy (target LDL-C ≥100 and <120 mg/dL)
Study: 24760537
Drug: Pasireotide 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 600 or 900 μg twice daily
Study: 15649196
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg daily for 8 weeks
Study: 8157043
Drug: Transnasal butorphanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transnasal butorphanol (2 mg) without oxymetazoline
Study: 8157043
Drug: Transnasal butorphanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transnasal butorphanol (2 mg) with oxymetazoline
Study: 8157043
Drug: Intravenous butorphanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous butorphanol (2 mg)
Study: 28968138
Drug: IIV4 (split-virion
Approvals — FDA: no, EMA: no, PMDA: no
Description: IIV4 (split-virion quadrivalent influenza vaccine)
Study: 27595443
Drug: IIV3 (trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: IIV3 (trivalent inactivated influenza vaccine)
Study: 17940203
Drug: epoetin or
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: epoetin or DAR treatment
Study: 17940203
Drug: less than
Normalized name: IgA less than or equal to 50 mcg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: less than 10% blasts, low and int‐1 International Prognostic Scoring System (IPSS), red blood cell transfusion independence, serum EPO level less than 200 IU/L
Study: 10443731
Drug: External beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: External beam radiotherapy with endocrine therapy
Study: 2192098
Drug: Oxprenolol (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol (160 mg initially, 320 mg subsequently)
Study: 2192098
Drug: Chlorthalidone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (50 mg daily)
Study: 2192098
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oxprenolol (160 mg and 320 mg) and chlorthalidone (25 mg and 50 mg)
Study: 2192098
Drug: Oxprenolol (monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol (monotherapy and combination therapy)
Study: 22901437
Drug: SMS reminders
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMS reminders for medication adherence
Study: 24200515
Drug: Bovine colostrum
Normalized name: Bovine Colostrum
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine colostrum (COL) 20g daily for 12 weeks
Study: 22778317
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (first-line chemotherapy followed by erlotinib)
Study: 10233190
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate (RBC) and two antibiotics (metronidazole, tetracycline) twice daily for 14 days
Study: 7418351
Drug: Metoclopramide (Primperan)
Normalized name: metoclopramide Oral Solution [Primperan]
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoclopramide (Primperan) administration prior to examination
Study: 6149595
Drug: Fluperlapine (200-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluperlapine (200-600 mg/day)
Study: 22301884
Drug: Mipomersen 200
Normalized name: mipomersen 200 mg/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mipomersen 200 mg/wk
Study: 22301884
Drug: Mipomersen 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mipomersen 300 mg/wk
Study: 22301884
Drug: Mipomersen 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mipomersen 100 mg/wk
Study: 22301884
Drug: Mipomersen (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mipomersen (100, 200, 300 mg/wk)
Study: 2229524
Drug: Topical terbinafine
Normalized name: terbinafine Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical terbinafine 1% cream
Study: 338872
Drug: Intramuscular iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular iron treatment
Study: 31808278
Drug: Combined ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Combined ranibizumab 0.5 mg/PRP
Study: 23816960
Drug: Afatinib 40
Normalized name: afatinib 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib 40 mg per day
Study: 17531723
Drug: Patient-controlled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled intravenous analgesia (PCA) with meperidine
Study: 1488694
Drug: ORS and
Normalized name: ACE inhibitors and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORS and Smectite (3.6 g/day) (32 cases)
Study: 1488694
Drug: ORS and
Normalized name: ACE inhibitors and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORS and Smectite (3.6 g/day)
Study: 3003729
Drug: Enalapril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (20 to 40 mg/day)
Study: 31904175
Drug: Oral hydrolyzed
Normalized name: collagen, hydrolyzed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hydrolyzed eggshell membrane (450 mg/d)
Study: 29789130
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (300 ml/day for men, 230 ml/day for women)
Study: 28316276
Drug: Levosimendan (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (0.2 μg/kg/min for 1 hour, followed by 0.1 μg/kg/min for 23 hours)
Study: 21765345
Drug: Amifostine (10-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifostine (10-100 mg/kg, intraperitoneal injection)
Study: 16053970
Drug: Ambrisentan 5
Normalized name: ambrisentan 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambrisentan 5 mg
Study: 16053970
Drug: Ambrisentan 10
Normalized name: ambrisentan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambrisentan 10 mg
Study: 16053970
Drug: Ambrisentan 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambrisentan 2.5 mg
Study: 16805144
Drug: Acetazolamide 250
Normalized name: acetazolamide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide 250 mg daily
Study: 1390316
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with carboplatin 400 mg/m2 day 1 and 5-FU 1 g/m2/d as a continuous infusion days 1 through 5 every 3 weeks, given to 108 patients.
Study: 1390316
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy group (not specified as control).
Study: 1390316
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (locoregional treatment alone).
Study: 31120943
Drug: Influenza vaccination
Normalized name: Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine Injection [PedvaxHIB]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccination (inactivated quadrivalent influenza vaccine)
Study: 26517576
Drug: Endoscopic variceal
Normalized name: VARICELLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic variceal ligation (EVL) + β-blocker
Study: 24092275
Drug: CISTIMEV PLUS(®),
Approvals — FDA: no, EMA: no, PMDA: no
Description: CISTIMEV PLUS(®), 1 tablet daily for 30 days
Study: 16883904
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (BQG + sulfasalazine)
Study: 7910472
Drug: Inhaled salmeterol
Normalized name: salmeterol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled salmeterol 100 micrograms
Study: 7910472
Drug: Inhaled salmeterol
Normalized name: salmeterol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled salmeterol (cumulative doses of up to 400 micrograms)
Study: 3540072
Drug: Intravenous streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous streptokinase (1.5 million IU/h)
Study: 24281606
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment on half of the wound surface
Study: 24281606
Drug: No insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No insulin treatment on the other half of the wound surface
Study: 17148968
Drug: Generic formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic formulation of stavudine (40 mg twice daily)
Study: 17148968
Drug: Generic formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic formulation of lamivudine (150 mg twice daily)
Study: 17148968
Drug: Generic formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic formulation of nevirapine (200 mg twice daily)
Study: 2701324
Drug: Behavioral Treatment
Normalized name: AspyreRx Digital Behavioral Therapeutic Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral Treatment Program
Study: 2701324
Drug: Methadone patients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone patients receiving additional medication for cocaine dependence
Study: 2701324
Drug: Inpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient treatment (28 days)
Study: 2701324
Drug: Outpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient treatment (day hospital or behavioral treatment)
Study: 302028
Drug: Isoprenaline inhalation
Normalized name: isoprenaline
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoprenaline inhalation test
Study: 23692260
Drug: Metoprolol succinate
Normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol succinate or olmesartan medoxomil (antihypertensive treatment)
Study: 21745623
Drug: BTE (333
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTE (333 mg)
Study: 16998649
Drug: Rivastigmine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine (3 to 12 mg per day)
Study: 11096003
Drug: Levofloxacin treatment
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin treatment
Study: 11096003
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy (not specified)
Study: 3304950
Drug: cyclandelate 800
Normalized name: Cyclandelate
DrugBank: Cyclandelate (DB04838)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclandelate 800 mg twice daily
Study: 3304950
Drug: flunarizine 5
Normalized name: flunarizine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: flunarizine 5 mg daily
Study: 27823681
Drug: Prasugrel 5mg
Normalized name: Prasugrel 5mg Oral tablet
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Prasugrel 5mg daily
Study: 27823681
Drug: Clopidogrel 75mg
Normalized name: clopidogrel 75 MG
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel 75mg daily
Study: 24602602
Drug: 5-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day course of amoxicillin/clavulanic acid 625 mg orally 8-hourly for 4 days after initial intravenous treatment
Study: 24602602
Drug: 1-day course
Normalized name: ESTRADIOL BENZOATE 1 kg in 1 kg POWDER [Estradiol Benzoate Coarse Grade]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-day course of amoxicillin/clavulanic acid 1.2g intravenously followed by placebo orally
Study: 22828247
Drug: Inspiratory loads
Normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory loads (light: 8.4 cm H2O/L/s, moderate: 23.4 cm H2O/L/s, severe: 70.5 cm H2O/L/s) with deep breaths during normal breathing
Study: 15942550
Drug: Oat bran
Normalized name: Oat bran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat bran cereal containing beta glucan (3 g daily)
Study: 10770343
Drug: Topical alitretinoin
Normalized name: alitretinoin Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical alitretinoin 0.1% gel
Study: 10770343
Drug: Open-label alitretinoin
Normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open-label alitretinoin treatment after blinded phase
Study: 8721798
Drug: Cholesterol-lowering treatments
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol-lowering treatments (specific types not detailed)
Study: 8721798
Drug: Hormone treatments
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone treatments
Study: 6139422
Drug: Luteinizing hormone
Normalized name: LUTEINIZING HORMONE
DrugBank: Luteinizing hormone (DB14741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteinizing hormone releasing hormone (LHRH)
Study: 25121977
Drug: Antidepressant cessation
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antidepressant cessation advice
Study: 11208829
Drug: Denileukin diftitox
Normalized name: Denileukin diftitox
DrugBank: Denileukin diftitox (DB00004)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Denileukin diftitox (both doses)
Study: 3296163
Drug: Clindamycin and
Normalized name: clindamycin and benzoyl peroxide KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin and gentamicin (C + G)
Study: 24766166
Drug: Weekly telephone
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly telephone calls
Study: 19010769
Drug: Intratumoural chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoural chemotherapy
Study: 16160615
Drug: Olanzapine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (10 mg/d, mean dose at endpoint 8.75 mg/day)
Study: 16160615
Drug: Risperidone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (4 mg/d, mean dose at endpoint 2.88 mg/d)
Study: 12893107
Drug: Short-term treatment
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term treatment of depression in patients with diabetes
Study: 12893107
Drug: Psychotherapy and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy and/or psychopharmacologic treatment
Study: 8857250
Drug: Chemiluminescent immunoassay
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemiluminescent immunoassay (CLIA) for thyroid stimulating hormone (TSH) and free-T4
Study: 8857250
Drug: Chemiluminescent immunoassay
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemiluminescent immunoassay (CLIA) for intact-parathyroid hormone (PTH)
Study: 1825315
Drug: HIV-1-infected persons
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: HIV-1-infected persons who received vaccine doses at the time of new HBV infection
Study: 6395212
Drug: Adjuvant cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant cyclophosphamide, vincristine, prednisone (CVP) chemotherapy with extended field radiotherapy (RT) in stage I patients.
Study: 25315941
Drug: Icy normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icy normal saline group (1,000 mL of 4°C normal saline intravenously)
Study: 22305917
Drug: 400-mcg buccal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400-mcg buccal misoprostol
Study: 22305917
Drug: 800-mcg buccal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800-mcg buccal misoprostol
Study: 15691349
Drug: Ibuprofen (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (200 mg tablets, twice daily)
Study: 10652038
Drug: Potassium-magnesium citrate
Normalized name: potassium magnesium aspartate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium-magnesium citrate (KMgCit; 42 mEq K, 21 mEq Mg, and 63 mEq citrate/day)
Study: 1944425
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of oral milrinone daily
Study: 26346122
Drug: Protocol B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol B (hyaluronic acid injection + low-level laser therapy)
Study: 26346122
Drug: Protocol A
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol A (sham light source + saline injection)
Study: 23707331
Drug: Nigella sativa
Normalized name: NIGELLA SATIVA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nigella sativa (NS) 500 mg capsule twice daily for nine weeks
Study: 21912062
Drug: Albendazole therapy
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole therapy for 12 weeks preoperatively and 12 weeks postoperatively
Study: 21912062
Drug: No preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preoperative albendazole therapy (control group)
Study: 12945071
Drug: Cox-2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cox-2 inhibitors
Study: 31207169
Drug: Fasinumab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasinumab (1 mg, 3 mg, 6 mg, or 9 mg) every 4 weeks for 16 weeks
Study: 31207169
Drug: Fasinumab (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasinumab (6 mg)
Study: 29944580
Drug: Carnoy's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carnoy's solution
Study: 29944580
Drug: Revision group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revision group (formalin specimens immersed in Carnoy's solution)
Study: 20678893
Drug: Heated patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heated patch (lidocaine 70 mg/tetracaine 70 mg)
Study: 20678893
Drug: Unheated patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unheated patch (lidocaine 70 mg/tetracaine 70 mg)
Study: 15844579
Drug: BCG‐SPN intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG‐SPN intramuscular injection (1ml, once every two days for 5 weeks)
Study: 15844579
Drug: Corticosteroid nasal
Normalized name: Corticosteroid nasal preparations for topical use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid nasal spray (once a day for 5 weeks)
Study: 15844579
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of BCG‐SPN and corticosteroid nasal spray (as above for 5 weeks)
Study: 12460131
Drug: Outpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient treatment approaches (5 types)
Study: 12460131
Drug: Outpatient drug-free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient drug-free programs for adults (previous DATCAP results)
Study: 9799979
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg mepivacaine 4% only
Study: 358713
Drug: Subcutaneous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous heparin (5000 U) administered 2 hours before surgery and every 8 hours for 6 days.
Study: 358713
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections administered to 47 operated patients.
Study: 25034442
Drug: Oleogel-S10 ointment
Normalized name: Oleogel-S10
DrugBank: Birch bark extract (DB16536)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oleogel-S10 ointment containing 10% birch bark extract
Study: 17348463
Drug: Clopidogrel (as
Normalized name: Clopidogrel (as clopidogrel besilate) 75 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (as a second antiplatelet drug)
Study: 17348463
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy without clopidogrel
Study: 11771654
Drug: Raloxifene (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (any dose)
Study: 9829138
Drug: 11-visit treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 11-visit treatment program
Study: 9802368
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (2 mg/kg)
Study: 8135557
Drug: Salbutamol (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (0.15 mg/kg every 30 minutes for the first three hours)
Study: 8135557
Drug: Salbutamol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (5 mg every one to four hours as needed)
Study: 23727002
Drug: HBsAg-1018 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBsAg-1018 (2 doses at 0 and 4 weeks)
Study: 23727002
Drug: HBsAg-Eng (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBsAg-Eng (3 doses at 0, 4, and 24 weeks)
Study: 9576383
Drug: DTaP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP plus oral polio vaccine (OPV)
Study: 9576383
Drug: DTaP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP plus eIPV (separate injections)
Study: 9576383
Drug: DTaP-eIPV combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP-eIPV combined as a single injection
Study: 9576383
Drug: DTaP-eIPV combined,
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP-eIPV combined, plus a separate injection of PRP-T
Study: 9576383
Drug: DTaP-eIPV combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP-eIPV combined and reconstituting PRP-T, as a single injection
Study: 9576383
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of DTaP reconstituting PRP-T as a single injection
Study: 1978163
Drug: Salmeterol 50
Normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 50 micrograms inhaled before allergen challenge
Study: 31856741
Drug: Impaired kidney
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impaired kidney function (eGFR < 60 ml/min/1.73m²)
Study: 31856741
Drug: Mildly impaired
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mildly impaired kidney function (eGFR 45-<60 ml/min/1.73m²)